Shire PLC’s (SHP) Buy Rating Reaffirmed at Liberum Capital
Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by research analysts at Liberum Capital in a report released on Monday. They currently have a GBX 5,500 ($73.26) target price on the biopharmaceutical company’s stock. Liberum Capital’s price target points to a potential upside of 7.95% from the company’s previous close.
Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 6,300 ($83.91) price target on shares of Shire PLC in a research note on Tuesday, August 23rd. Shore Capital restated a “buy” rating on shares of Shire PLC in a research note on Tuesday, August 30th. HSBC restated a “buy” rating and set a GBX 5,400 ($71.92) price target on shares of Shire PLC in a research note on Tuesday, September 13th. Jefferies Group restated a “buy” rating and set a GBX 6,600 ($87.91) price target on shares of Shire PLC in a research note on Monday, September 12th. Finally, BNP Paribas restated an “outperform” rating and set a GBX 5,700 ($75.92) price target on shares of Shire PLC in a research note on Wednesday, June 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Shire PLC currently has a consensus rating of “Buy” and a consensus price target of GBX 5,841.33 ($77.80).
Shares of Shire PLC (LON:SHP) opened at 5105.00 on Monday. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,180.00. The firm has a 50-day moving average price of GBX 4,943.59 and a 200-day moving average price of GBX 4,416.34. The firm’s market capitalization is GBX 34.86 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/shire-plcs-shp-buy-rating-reaffirmed-at-liberum-capital.html
The company also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be given a dividend of GBX 3.51 ($0.05) per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a dividend yield of 0.07%.
In other news, insider Bohuon,Olivier purchased 134 shares of Shire PLC stock in a transaction dated Thursday, June 30th. The shares were bought at an average cost of GBX 4,463 ($59.44) per share, with a total value of £5,980.42 ($7,965.40).
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Shire PLC and related companies with MarketBeat.com’s FREE daily email newsletter.